30 June 2025
On 30 June 2025, the National Healthcare Security Administration and the National Health Commission (“the authorities”) issued the “Notice of Issuing Several Measures for Supporting the High-quality Development of Innovative Drugs” (“the Measures”). The authorities announced to promote the global expansion of innovative drugs from China through the support of innovative pharmaceutical companies by leveraging the relevant advantages from Hong Kong and Macao.